Trial News & Events

Progress coming in amyotrophic lateral sclerosis, but rigorous studies needed

The community of individuals living with amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, has endured many false hopes for promising therapies and is still waiting for the first disease-modifying drug. Nevertheless, "we have made huge progress in the last decade in ALS," Merit Cudkowicz, professor of neurology at Harvard Medical School and chief of the neurology service and director of the MDA ALS Clinic at Massachusetts General Hospital, told participants in an integrated neuroscience session on ALS at the American Academy of Neurology (AAN) 67th annual meeting. Read the entire article

NEALS Members Attend the American Academy of Neurology Annual Meeting in Washington, DC

The 67th American Academy of Neurology Annual Meeting took place in Washington, DC on April 22. This year, an overwhelming number of NEALS members were invited to participate; the membership gave multiple plenary talks, served as session chairs, participated in platform presentations, and presented over 25 abstract posters over the week-long program. If you weren't able to join in person for the event this year, all abstracts can be found

FDA ALS Statement

[FDA] call upon Genervon to release all the data from their recently completed trial in order to allow a more informed discussion of the trial findings among ALS stakeholders. Read the entire statement here.…

The ALS Association, Harvard Stem Cell Institute, and Massachusetts General Hospital Neurological Cl

The ALS Association, Harvard Stem Cell Institute, and Massachusetts General Hospital Neurological Clinical Research Institute today announced they are collaborating with GlaxoSmithKline (GSK) on a clinical trial to evaluate the potential of an anti-epileptic drug in ALS patients. The trial will evaluate the potential of the drug, Retigabine, which has a unique mechanism of action and can calm the excitability of nerve cells that are thought to cause seizures. Read the entire press release here.…

Ultra-high dose methylcobalamin (E0302) prolongs survival of ALS

Report of 7 years’ randomised double-blind, phase 3 clinical trial The present study demonstrated for the first time that ultra-high dose methylcobalamin can significantly prolong survival and retard progression in ALS if administered early. Read the full abstract here.…

Neuralstem Announces Topline Results of Phase II Trial

Neuralstem, Inc. announced top-line data from the Phase II trial of NSI-566 spinal cord-derived neural stem cells under development for the treatment of ALS. The maximum tolerated dose of 16 million transplanted cells and the surgery was well tolerated. "We were very excited to participate as a site in this clinical trial," said Merit Cudkowicz, MD, Chief of Neurology, Massachusetts General Hospital and Co-Chair of NEALS." We are hopeful with respect to the top-line results and it is important to move swiftly and safely forward to a larger, confirmatory safety and efficacy study." The NEALS data…

The 25th Annual MND/ALS Symposium

The 25th Annual Symposium was held from December 5th – 7th in Brussels, Belgium. The International MND/ALS Symposium is the largest annual MND/ALS conference with over 900 researchers in attendance from around the globe. 

ALS Researchers Appear on “The Doctors”

NEALS Co-Chair Merit Cudkowicz, MD, MSc (Massachusetts General Hospital) and NEALS member Robert Baloh, MD, PhD (Cedars-Sinai) appeared on an episode of "The Doctors" with PALS Nanci Ryder, a celebrity publicist who opened up about her ALS diagnosis. Check your local listings for show times, and view a short clip and article about the episode here.…

PALS Speaks to Congress about ALS Research

Attorney and PALS Michael Gollin spoke to Congress November 18th about how they can help change the balance of risks to favor successful innovation in ALS research, and why they should adopt the MODERN Cures Act. You can read Michael’s full testimony at the MODDERN Cures Act Briefing here.…